Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMAZ | ISIN: SE0018013849 | Ticker-Symbol: PBC
Frankfurt
24.01.25
08:03 Uhr
0,346 Euro
+0,002
+0,58 %
1-Jahres-Chart
PRECISE BIOMETRICS AB Chart 1 Jahr
5-Tage-Chart
PRECISE BIOMETRICS AB 5-Tage-Chart
GlobeNewswire (Europe)
60 Leser
Artikel bewerten:
(0)

Precise Biometrics AB: Positive Momentum For Long-term Growth

Finanznachrichten News

INTERIM REPORT FOR THE PERIOD JANUARY TO JUNE 2024

SECOND QUARTER?

  • Net sales totaled SEK 20.6 (17.9) million?
  • EBITDA totaled SEK 0.1 (-0.6) million?
  • The operating profit/loss for the quarter totaled SEK -5.7 (-6.9) million?
  • Earnings for the period totaled SEK -5.6 (-6.8) million??
  • Earnings per share totaled SEK -0.07 (-0.09)?
  • Cash flow from operations totaled SEK 3.9 (5.4) million?
  • ARR (Annual Recurring Revenue) at the end of the period was SEK 18.6 (17.8) million.
    ?

INTERIM PERIOD?

  • Net sales totaled SEK 42.3 (37.0) million?
  • EBITDA totaled SEK 3.2 (-1.2) million?
  • The operating profit/loss totaled SEK -8.5 (-13.8) million?
  • Earnings for the period totaled SEK -8.5 (-13.7) million??
  • Earnings per share totaled SEK -0.11 (-0.18)?
  • Cash flow from operations totaled SEK 1.0 (-0.4) million?
  • ARR (Annual Recurring Revenue) at the end of the period was SEK 18.6 (17.8) million.?
    ?

SIGNIFICANT EVENTS DURING THE QUARTER?

  • Demonstrated biometric recognition solutions at ISC West and Embedded World?
  • Extended partnership with Flowscape Technology and new customer agreement?
  • Upgraded AI-driven anti-tampering and liveness solution
  • CEO Joakim Nydemark presented at Redeye Growth Day 2024??
  • Maria Wester recruited as new Chief Financial Officer (CFO) and member of the management team.?
  • Stronger commitment to ultrasonic fingerprint solutions. ?
    ?

SIGNIFICANT EVENTS AFTER THE END OF THE INTERIM PERIOD??

  • No significant events after the end of the quarter.??

PRESENTATION AND Q&A?

Precise Biometrics has published a video interview with CEO Joakim Nydemark in which he comments on the report. The video is available on the Investor Relations page: https://precisebiometrics.com/investors/.??

The video is designed to complement the report and provide additional depth and better understanding on the financial markets for the company's business operations.?

The company also invites you to a LIVE Q&A that starts at 13:00 AM (CET) on August 16, 2024, which can be reach here:
https://www.youtube.com/watch?v=mJDhIkUkitQ

Questions can be asked directly in the chat function or submitted in advance to investor@precisebiometrics.com?

The video and live Q&A will be held in Swedish, but it is possible to ask questions and get answers in English as well.

JOAKIM NYDEMARK, CEO, COMMENTS:

"The second quarter has seen further steps forward on our commercialization journey. Several new and exciting customer projects with partners involving our algorithm products have been launched, with production and revenue expected in the second half of the year and beyond. The investment in the Netherlands is starting to generate revenue and our updated offerings for increased security with BioLive and multi-factor authentication have been well received by both new and existing customers.
?
We continue to show an operating profit before depreciation (EBITDA) for the third quarter in a row; SEK 3.2 (-1.2) million for the first half of 2024. Net sales were also up year-on-year in the first half of 2024 to SEK 42.3 (37.0) million. Sales costs increased in the second quarter compared to the first, an effect brought about by investments in marketing and sales that impacts EBITDA. We are confident that these well-balanced initiatives will have a positive effect on net sales going forward."?

Contacts

Joakim Nydemark, CEO
E-mail: joakim.nydemark@precisebiometrics.com

About Us

Precise Biometrics AB (publ) ("Precise"), is a global pioneer in biometric IT security solutions. The biometric recognition solution suite today includes fingerprint, face, and palm recognition algorithm products along with turnkey solutions for visitor management (YOUNiQ Visit - EastCoast Visit in Sweden) and biometric access management (YOUNiQ Access).

Precise's premium biometric recognition solutions is used in mobiles, laptops, security tokens and smart looks, as well as automotive applications for in-car payments, driver authentication, and personalized settings and access. Precise also offer visitor management and physical biometric access control solutions.

Precise operates through two business units, Digital Identity and Biometric Technologies, and the company has offices in Lund (HQ) and Stockholm, Sweden, Potsdam NY, USA, Seoul, South Korea, Taipei, Taiwan, and Shanghai, China. Precise is a public company with shares listed on Nasdaq Stockholm (PREC). Learn more at www.precisebiometrics.com.

This information is information that Precise Biometrics is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-16 08:00 CEST.

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.